Coca‑Cola Stock Climbs on Zero Sugar, EPS Strength

Introduction

This week Coca‑Cola (KO) showed renewed strength as investors digested a mix of concrete earnings outcomes, category performance data, and analyst reactions. Solid profitability and standout growth in zero‑sugar sparkling beverages helped the shares rebound near their 52‑week highs, even as a top‑line miss and an impairment tied to BodyArmor introduced caution. The facts below distill what moved KO this week and why those developments matter to shareholders.

Key Earnings and Financial Signals

Q4 results: profit beat, revenue miss

Coca‑Cola reported adjusted EPS better than expectations, driven by margin discipline and effective pricing, while revenue came in slightly below consensus. The company recorded roughly $11.8 billion in quarterly revenue versus about $12.0 billion expected, but adjusted EPS of about $0.58 topped estimates. That divergence—profits holding up despite a softer top line—is central to the market reaction this week.

BodyArmor impairment and guidance

Management disclosed an impairment related to BodyArmor approaching nearly $1 billion, which drew attention because sports drinks are a high‑growth segment. At the same time, management provided measured guidance for 2026: organic revenue growth in the mid single digits and earnings growth in the high single digits. The market balanced the impairment hit against the company’s longer‑term margin story.

Category Performance: Winners and Laggards

Zero Sugar and sparkling strength

Zero‑sugar variants were the standout. Coca‑Cola Zero Sugar posted double‑digit growth (about +13% for the quarter and ~14% for the full year), reinforcing the ongoing consumer shift toward reduced‑sugar options. Sparkling brands overall were resilient—Trademark Coca‑Cola showed modest growth—helping the concentrate business offset softer pockets elsewhere.

Hydration, tea, and sports drinks

Hydration and tea categories delivered respectable gains: tea volumes improved materially quarter‑over‑quarter, water grew mid‑single digits QoQ, and sports drinks showed positive momentum on a quarterly basis. These categories provide recurring, stable demand that underpins Coca‑Cola’s defensive characteristics.

Pressure in juice, dairy and plant‑based

Juice, value‑added dairy, and plant‑based beverages were weak, declining roughly 3% in both quarterly and annual comparisons. Underperformance in regions such as Asia Pacific and EMEA, plus the impact of a recent divestiture in Nigeria, are the main drivers of that weakness.

Market Reaction and Analyst Moves

Share price action this week

KO shares advanced in multiple sessions, trading close to and briefly near 52‑week highs as investors rewarded EPS resilience and category gains. Notable intraday moves included midweek rallies that outpaced peers in the beverage space, reflecting demand for defensive, high‑quality names amid mixed macro headlines.

Analyst sentiment: upgrades and caution

Analysts were split. Some firms raised price targets—citing steady cash flow, brand durability, and success in zero‑sugar innovation—while others warned that valuations have already priced much of the company’s defensive appeal. A raised UBS price target in the $80s reinforced the buy case, but cautionary notes on limited near‑term upside were common among more valuation‑focused analysts.

What Investors Should Focus On Now

Execution on high‑growth categories

Watch BodyArmor’s path to recovery and whether management can restore momentum in sports hydration without sacrificing margins. Success there would materially affect both top‑line trajectory and investor sentiment.

Geographic recovery and product mix

Recovery in Asia Pacific and EMEA, where juice and plant‑based categories lagged, will be important. More broadly, continued shift toward zero‑sugar variants and hydration should help sustain organic revenue growth without the volatility of more experimental segments.

Conclusion

This week’s developments paint a nuanced picture for Coca‑Cola: profitability and category wins in zero‑sugar and hydration supported the stock, while a revenue shortfall and a sizeable impairment for BodyArmor tempered enthusiasm. For investors, the near‑term tradeoff is clear—robust earnings execution versus questions about growth stability in some categories and valuation headroom. The coming quarters will hinge on whether Coca‑Cola can convert its pricing and mix advantages into sustained top‑line momentum across key regions and brands.